Adelaide Eye and Retina Centre | Adelaide, South Australia
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of intravitreal 6-mg faricimab administered at up to 24-week intervals in patients with neovascular age-related macular degeneration (nAMD) that are treatment-naïve in the study eye.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Ocular Inclusion Criteria for Study Eye:
Exclusion criteria
Ocular Exclusion Criteria for Study Eye:
Ocular Exclusion Criteria for Fellow (Non-Study) Eye:
Ocular Exclusion for Both Eyes:
Primary purpose
Allocation
Interventional model
Masking
274 participants in 2 patient groups
Loading...
Central trial contact
Reference Study ID Number: MR45638 https://forpatients.roche.com/
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal